<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Biotech on AI Brief | AI-101.tech</title><link>https://AI-101.tech/categories/biotech/</link><description>Recent content in Biotech on AI Brief | AI-101.tech</description><generator>Hugo</generator><language>en</language><lastBuildDate>Wed, 29 Apr 2026 00:00:00 +0000</lastBuildDate><atom:link href="https://AI-101.tech/categories/biotech/index.xml" rel="self" type="application/rss+xml"/><item><title>CIK Cell Therapy in 2024-2025: CAR-CIK, DC-CIK Combos, and the Birth of ISCC</title><link>https://AI-101.tech/posts/2026-04-29-cik-cell-therapy-clinical-trends-2024-2025/</link><pubDate>Wed, 29 Apr 2026 00:00:00 +0000</pubDate><guid>https://AI-101.tech/posts/2026-04-29-cik-cell-therapy-clinical-trends-2024-2025/</guid><description>&lt;h2 id="three-years-of-progress-one-milestone-iscc-founded"&gt;Three Years of Progress, One Milestone: ISCC Founded&lt;/h2&gt;
&lt;p&gt;When the first International CIK Cell Conference convened in August 2023, it marked the 30th anniversary of cytokine-induced killer cell therapy with a simple mission: standardize what works. Two years later, the field has not stood still. On April 7, 2025, the &lt;strong&gt;2nd International CIK Cell Conference&lt;/strong&gt; convened in Monza, Italy, and the most tangible output was the founding of the &lt;strong&gt;International Society for CIK Cells (ISCC)&lt;/strong&gt; — a formal body that will coordinate preclinical research, clinical trials, and — critically — the production protocols that have long held the field back.&lt;/p&gt;</description></item></channel></rss>